BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the Sidoti December Small Cap Conference, taking place virtually from December 6-7, 2023. Details are as follows:
Sidoti December Small Cap Conference
Format: Company Presentation
Date and Time: Wednesday, December 6, 2023, from 12:15 pm - 12:45 pm EST
Location: Virtual
A live webcast of the presentation can be accessed from the Investors section of the Athira website or by clicking here.. An archived replay will be available for at least 30 days following the event.
Athira Pharma will also host virtual one-on-one meetings with investors on Wednesday, December 6 and Thursday, December 7. To register for the conference and schedule a one-on-one meeting, please visit https://sidoti.com/events.
About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological disease by advancing its pipeline of therapeutic candidates targeting the HGF neurotrophic system for Alzheimer’s and Parkinson’s disease, Dementia with Lewy bodies, and amyotrophic lateral sclerosis. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on X, formerly known as Twitter, and Instagram.
Investor & Media Contact:
Julie Rathbun
Athira Pharma
This email address is being protected from spambots. You need JavaScript enabled to view it.
206-769-9219
Last Trade: | US$0.43 |
Daily Change: | -0.02 -4.68 |
Daily Volume: | 292,559 |
Market Cap: | US$16.460M |
October 22, 2024 September 17, 2024 September 03, 2024 August 01, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB